Masimo (NASDAQ:MASI) Posts Quarterly Earnings Results

Masimo (NASDAQ:MASI) posted its quarterly earnings results on Tuesday. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.09, Briefing.com reports. Masimo had a net margin of 4.01% and a return on equity of 13.26%. The business had revenue of $496.30 million for the quarter, compared to analysts’ expectations of $493.92 million. During the same period in the prior year, the company posted $0.62 EPS. The business’s revenue for the quarter was up 9.0% on a year-over-year basis.

Masimo Price Performance

Shares of MASI traded down $1.07 during trading hours on Friday, reaching $126.87. 651,209 shares of the company traded hands, compared to its average volume of 677,744. The stock has a market capitalization of $6.75 billion, a PE ratio of 87.76 and a beta of 0.97. The stock has a fifty day simple moving average of $118.82 and a 200 day simple moving average of $127.81. Masimo has a fifty-two week low of $75.22 and a fifty-two week high of $153.93. The company has a quick ratio of 1.31, a current ratio of 2.31 and a debt-to-equity ratio of 0.62.

Analyst Upgrades and Downgrades

MASI has been the topic of several recent analyst reports. Stifel Nicolaus upgraded shares of Masimo from a “hold” rating to a “buy” rating and upped their target price for the stock from $148.00 to $170.00 in a research report on Monday, April 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday. Finally, Piper Sandler lifted their price objective on Masimo from $160.00 to $165.00 and gave the stock an “overweight” rating in a report on Wednesday. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Masimo currently has an average rating of “Moderate Buy” and a consensus price target of $144.29.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.